Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Part D Out-Of-Pocket Cap Would Be $2,000 In House Drug Pricing Bill

It may seem perverse to look for silver linings for the drug industry in the House leaderships “price negotiation” bill. But if you can get past Title 1, the bill reads like an attempt to negotiate with the Senate Finance Committee – and it’s not all bad.

Latest From Pricing Debate

FTC Vote On BMS-Celgene Acquisition Splits Over Drug Pricing

Divesting Celgene's psoriasis drug Otezla will remedy anticompetitive harm from acquisition, US Federal Trade Commission votes 3-2. Dissenting Democrat commissioners want broader review of pharma mergers.

M & A Enforcement

WHO Moves To Reduce Insulin Prices By Widening Supply

Including human insulin in the World Health Organization’s quality assurance scheme should lead to lower prices and wider availability in resource-poor regions of the world. The move has been welcomed by medicines access advocates.

International Biologics

How To Make Cross-Country Collaborations On Pricing Work

Francis Arickx from the cross-country coalition BeNeLuxA spoke this month about how the initiative had delivered proof of concept and discussed why uniting across borders is important for delivering access to transformative but expensive medicines.  

Europe Health Technology Assessment

NGOs Urge Italian Govt Not To Replace Head Of Drugs Agency

The Italian health ministry is looking for someone to take over as director general of the medicines agency AIFA. The move has shocked health activists who see Luca Di Bassi as a champion of drug price transparency.

Italy Regulation

Importation, Pricing Policies Raised Concerns For US FDA's Project Orbis

Allowing multi-regulator collaboration on oncology application assessment may run into pricing issues if Canada and Australia gain access to novel drugs before European countries, US FDA's Pazdur says.

Pricing Debate Drug Review

Trump's International Pricing Proposal Being Revised To Adopt ‘Most Favored Nation’ Policy – Azar

HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.

Pricing Debate Regulation

International Horizon Scanning Initiative To Level Pricing Playing Field

Nine countries are joining forces on horizon scanning with the aim of improving their chances of securing lower prices for high-cost drugs.

Europe International

Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues

TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which is part of an oral combination regimen, and maintains that the $1/day pricing ask for the drug is based on flawed assumptions and not currently feasible.

Commercial Strategy

Fair Pricing A Key Feature Of NHS England Drug Funding Proposals

Plans for a new commercial framework for publicly funded medicines in England are out for consultation. The concept of fair and responsible pricing figures large in the proposals.

Pricing Debate United Kingdom
See All
UsernamePublicRestriction

Register